| Company/Division name | Jaguar Gene Therapy |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 14.1 |
| City reshored to: | Durham |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | therapeutics |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Government Incentives |
| Government Incentive dollar amount: | $14.1 million |
